Citations

Showing 10 of 108152 citations.

Letter: safety of immune checkpoint inhibitors in patients with pre‐established microscopic colitis—a single‐centre experience
Fredrick, Thomas , Neto, Manuel B. Braga , Ramos, Guilherme Piovezani , Kane, Sunanda V. , Pardi, Darrell S. , Raffals, Laura E. , Fredrick, Thomas W , Braga Neto, Manuel B, Ramos, Guilherme P, Kane, S , Braga Neto, Manuel B , Ramos, Guilherme P

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 25, 2021 | Volume: 54 | Issue: 2 | Pages: 217-218

10.1111/apt.16458 | PMID 34170536 Get It

LINKED CONTENT This article is linked to Meserve et al paper. To view this article, visit https://doi.org/10.1111/apt.16217
Glial‐derived neurotrophic factor in human airway smooth muscle
Bhallamudi, Sangeeta, Roos, B., Teske, Jacob J. , Wicher, Sarah A. , McConico, Andrea L., Pabelick, Christina M. , Sathish, Venkatachalem , Prakash, Y. S. , Roos, Benjamin B, Pabelick, Christina M , Prakash, Y S , Sathish, Venkatachalem , Teske, Jacob J

Mayo Clinic

Journal of Cellular Physiology | June 25, 2021 | Volume: 236 | Issue: 12 | Pages: 8184-8196

10.1002/jcp.30489 | PMID 34170009 Get It

AbstractAirway smooth muscle (ASM) cells modulate the local airway milieu via production of inflammatory mediators and growth factors including classical neurotrophins, such as brain‐derived neurotrophic factor (BDNF). The glial cell‐derived neurotrophic factor (GDNF) family of ligands (GFLs) are nonclassical neurotrophins and their role in the airway is barely understood. The major GFLs, GDNF and Neurturin (NRTN) bind to GDNF family receptor (GFR) α1 and α2 respectively that pair with Ret receptor to accomplish signaling. In this study, we found GDNF is expressed in human lung and increased in adult asthma, while human ASM expresses GDNF and its receptors. Accordingly, we used human ASM cells to test the hypothesis that ASM expression and autocrine signaling by GFLs regulate [Ca2+]i. Serum‐deprived ASM cells from non‐asthmatics were exposed to 10 ng/ml GDNF or NRTN for 15 min (acute) or 24 h (chronic). In fura‐2 loaded cells, acute GDNF or NRTN alone induced [Ca2+]i responses, and further enhanced responses to 1 µM ACh or 10 µM histamine. Ret inhibitor (SPP86; 10 µM) or specific GDNF chelator GFRα1‐Fc (1 µg/ml) showed roles of these receptors in GDNF effects. In contrast, NRTN did not enhance [Ca2+]i response to histamine. Furthermore, conditioned media of nonasthmatic and asthmatic ASM cells showed GDNF secretion. SPP86, Ret inhibitor and GFRα1‐Fc chelator markedly decreased [Ca2+]i response compared with vehicle, highlighting autocrine effects of secreted GDNF. Chronic GDNF treatment increased histamine‐induced myosin light chain phosphorylation. These novel data demonstrate GFLs particularly GDNF/GFRα1 influence ASM [Ca2+]i and raise the possibility that GFLs are potential targets of airway hyperresponsiveness.
Screening for Regenerative Therapy Responders in Heart Failure
Yamada, Satsuki , Jeon, Ryoung‐Hoon , Garmany, Armin , Behfar, Atta , Terzic, André , Jeon, Ryounghoon , Behfar, Atta , Terzic, Andre

Mayo Clinic

Biomarkers in Medicine | June 25, 2021 | Volume: 15 | Issue: 10 | Pages: 775-783

10.2217/bmm-2020-0683 | PMID 34169733 Get It

Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome
May, Heather P. , Mara, Kristin C. , Frazee, Erin N. , Leung, Nelson , Frazee, Erin N , Personett, Heather A. , Leung, Nelson , Mara, Kristin C , Habermann, Thomas M.

Mayo Clinic

Leukemia & Lymphoma | June 25, 2021 | Volume: 62 | Issue: 13 | Pages: 3152-3159

10.1080/10428194.2021.1941931 | PMID 34169786 Get It

Editorial Commentary
Andrews, Jack R. , Koo, Kevin

Mayo Clinic

Urology Practice | June 25, 2021 | Volume: 8 | Issue: 5 | Pages: 603-603

10.1097/upj.0000000000000246.02 | PMID 37145409 Get It

Ubiquitination is essential for recovery of cellular activities after heat shock
Maxwell, Brian A. , Gwon, Youngdae , Mishra, Ashutosh , Peng, Junmin , Nakamura, Haruko , Zhang, Ke , Kim, Hong Joo , Taylor, J. Paul , Zhang, Ke , Taylor, J Paul

Mayo Clinic

Science | June 24, 2021 | Volume: 372 | Issue: 6549 | Pages: No page available

10.1126/science.abc3593 | PMID 34739326 Get It

Tailoring stress responses When faced with environmental stress, cells respond by shutting down cellular processes such as translation and nucleocytoplasmic transport. At the same time, cells preserve cytoplasmic messenger RNAs in structures known as stress granules, and many cellular proteins are modified by the covalent addition of ubiquitin, which has long been presumed to reflect degradation of stress-damaged proteins (see the Perspective by Dormann). Maxwell et al. show that cells generate distinct patterns of ubiquitination in response to different stressors. Rather than reflecting the degradation of stress-damaged proteins, this ubiquitination primes cells to dismantle stress granules and reinitiate normal cellular activities once the stress is removed. Gwon et al. show that persistent stress granules are degraded by autophagy, whereas short-lived granules undergo a process of disassembly that is autophagy independent. The mechanism of this disassembly depends on the initiating stress. Science , abc3593 and abf6548, this issue p. eabc3593 and p. eabf6548 ; see also abj2400, p. 1393
Simultaneous Use of Hypertonic Saline and IV Furosemide for Fluid Overload: A Systematic Review and Meta-Analysis
Liu, Chang , Peng, Zhiyong , Gao, Xiaolan , Domecq, Juan Pablo , Domecq Graces, Juan Pablo , Gajic, Ognjen , Dong, Yue , Prokop, Larry J. , Murad, M. Hassan , Kashani, Kianoush

Mayo Clinic

Critical Care Medicine | June 24, 2021 | Volume: 49 | Issue: 11 | Pages: e1163-e1175

10.1097/ccm.0000000000005174 | PMID 34166286 Get It

OBJECTIVES: To evaluate the efficacy of the simultaneous hypertonic saline solution and IV furosemide (HSS+Fx) for patients with fluid overload compared with IV furosemide alone (Fx). DATA SOURCES: Electronic databases (MEDLINE, EMBASE, CENTRAL, Cochrane Database of Systematic Reviews, PsycINFO, Scopus, and WOS) were searched from inception to March 2020. STUDY SELECTION: Randomized controlled trials on the use of HSS+Fx in adult patients with fluid overload versus Fx were included. DATA EXTRACTION: Data were collected on all-cause mortality, hospital length of stay, heart failure–related readmission, along with inpatient weight loss, change of daily diuresis, serum creatinine, and 24-hour urine sodium excretion from prior to post intervention. Pooled analysis with random effects models yielded relative risk or mean difference with 95% CIs. DATA SYNTHESIS: Eleven randomized controlled trials comprising 2,987 acute decompensated heart failure patients were included. Meta-analysis demonstrated that HSS+Fx was associated with lower all-cause mortality (relative risk, 0.55; 95% CI, 0.46–0.67; p < 0.05; I2 = 12%) and heart failure–related readmissions (relative risk, 0.50; 95% CI, 0.33–0.76; p < 0.05; I2 = 61%), shorter hospital length of stay (mean difference, –3.28 d; 95% CI, –4.14 to –2.43; p < 0.05; I2 = 93%), increased daily diuresis (mean difference, 583.87 mL; 95% CI, 504.92–662.81; p < 0.05; I2 = 76%), weight loss (mean difference, –1.76 kg; 95% CI, –2.52 to –1.00; p < 0.05; I2 = 57%), serum sodium change (mean difference, 6.89 mEq/L; 95% CI, 4.98–8.79; p < 0.05; I2 = 95%), and higher 24-hour urine sodium excretion (mean difference, 61.10 mEq; 95% CI, 51.47–70.73; p < 0.05; I2 = 95%), along with decreased serum creatinine (mean difference, –0.46 mg/dL; 95% CI, –0.51 to –0.41; p < 0.05; I2 = 89%) when compared with Fx. The Grading of Recommendation, Assessment, Development, and Evaluation certainty of evidence ranged from low to moderate. CONCLUSIONS: Benefits of the HSS+Fx over Fx were observed across all examined outcomes in acute decompensated heart failure patients with fluid overload. There is at least moderate certainty that HSS+Fx is associated with a reduction in mortality in patients with acute decompensated heart failure. Factors associated with a successful HSS+Fx utilization are still unknown. Current evidence cannot be extrapolated to other than fluid overload states in acute decompensated heart failure.
Work Patterns of Women Physicians During Vacation: A Cross-Sectional Study
Marshall, Ariela L. , Elafros, Melissa A. , Duma, Narjust , Marshall, Ariela

Mayo Clinic

Journal of Women's Health | June 24, 2021 | Volume: 31 | Issue: 4 | Pages: 573-579

10.1089/jwh.2021.0100 | PMID 34166095 Get It

Background: Burnout and poor work–life integration (WLI) are prevalent among women physicians. Vacation may help alleviate burnout and improve WLI but working while on vacation may negate these potential benefits. Little is known about the work patterns of women physicians on vacation, and we attempted to further characterize it in this study. Methods: In this online cross-sectional study of 498 members of the Physician Women in Leadership Facebook Group, we collected demographic information, information regarding burnout/WLI, self-reported work patterns while on vacation, and perceived impact of working during vacation on burnout/WLI. We also asked about the impact of the COVID-19 pandemic on these behaviors. Results: At baseline, 37.5% of respondents reported burnout and 58.4% reported lack of satisfaction with WLI. About 94.4% of respondents reported engaging in some level of work-related behavior while on vacation (primarily answering work-related emails and participating in work-related meetings), but 73.3% reported that such engagement was detrimental to their mental health and WLI. About 66.3% reported an increase in at least one work-related behavior on vacation during the COVID-19 pandemic. Respondents identified and/or endorsed multiple strategies to reduce work-related engagement on vacation, many involving good modeling by leadership and/or national associations. Conclusions: Engagement in work-related behavior while on vacation is almost universal among women physicians, but most feel that it has negative effects on mental health and WLI. Strategies to encourage reduced engagement should be developed/strengthened and endorsed/modeled by those in leadership.
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme
Farraye, Francis A. , Qazi, Taha , Kotze, Paulo Gustavo , Moore, Gregory , Mundayat, Rajiv , Lawendy, Nervin, Sharma, Puza P. , Judd, Donna T., Kotze, Paulo G , Moore, Gregory T , Farraye, Francis A

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 24, 2021 | Volume: 54 | Issue: 4 | Pages: 429-440

10.1111/apt.16439 | PMID 34165201 Get It

SummaryBackgroundObesity may affect efficacy and safety of biologic treatments for ulcerative colitis (UC). Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC.AimsTo assess efficacy and safety of tofacitinib in patients with UC, by baseline body mass index (BMI).MethodsThis post hoc analysis evaluated patients with UC receiving placebo or tofacitinib from the 8‐week OCTAVE Induction 1 and 2 (NCT01465763, NCT01458951) and 52‐week OCTAVE Sustain (NCT01458574) studies. Patients were stratified by BMI at OCTAVE Induction 1 and 2 baseline (<25, 25 to <30 and ≥30 kg/m2). Outcomes included remission, endoscopic improvement, clinical response, sustained steroid‐free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form‐36 Health Survey scores. Adverse events were evaluated.ResultsAt Week 8 of OCTAVE Induction 1 and 2, and Week 52 of OCTAVE Sustain, higher proportions of patients receiving tofacitinib 5 or 10 mg twice daily (b.d.) achieved clinical response vs placebo, regardless of baseline BMI subgroup (all P < 0.05). Proportions of patients achieving efficacy endpoints were generally similar across BMI subgroups; in univariate and multivariate regression analyses, BMI was not a significant predictor (all P ≥ 0.05; univariate BMI [continuous] odds ratio for remission: 0.98 [95% confidence interval 0.95, 1.02]). There was no consistent trend between BMI and adverse events. Among patients receiving tofacitinib 10 mg b.d. in OCTAVE Induction 1 and 2, serious infections were numerically greater in the BMI ≥30 subgroup (3.2%) vs other subgroups (0.4%). Limitations included small patient numbers in the BMI ≥30 subgroup.ConclusionsEfficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI.
Faculty Opinions recommendation of When does obstetric coagulopathy occur and how do I manage it?
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.740246753.793586295 Get It